Risankizumab vs Icotrokinra for Psoriasis

With multiple high-performing agents now available for moderate to severe psoriasis (PsO), clinicians increasingly face a decision not between effective and ineffective therapy but among options that differ in mechanism, route, dosing schedule, and depth of long-term evidence. Comparative effectiveness data — including indirect analyses presented at major dermatology meetings — can inform these distinctions, but their clinical utility depends on a working standard for when observed numerical differences in response rates are large enough to matter in practice. Across PASI 90 and PASI 100 endpoints, absolute differences of approximately 7% to 10% or greater typically correspond to advantages that are clinically discernible — representing a meaningful proportion of additional patients achieving the outcome that defines therapeutic success in PsO. Differences below approximately 5% are rarely distinguishable at the bedside and generally should not drive agent selection in isolation. This framework is most useful when applied alongside consideration of the methodological quality of the underlying analysis and its congruence with pivotal trial data and real-world clinical experience.

Indirect comparison data presented at recent major dermatology meetings comparing risankizumab and icotrakinra across PASI response thresholds and time points have demonstrated consistently higher placebo-adjusted response rates for risankizumab. Applied against the clinical threshold framework above, this difference reflects a real efficacy advantage for risankizumab that is relevant in practice — particularly for patients in whom maximum achievable skin clearance is the primary goal. Icotrakinra's phase 3 data through 1 year are considered robust, and its PASI 90 response rates of approximately two-thirds of patients at week 24 represent a meaningful advance for the oral therapy category. However, multi-year durability data comparable to those now available for risankizumab and other established IL-23 biologics have not yet been generated for icotrakinra, and this evidence gap is a practical consideration when selecting between an established biologic with a decade of real-world experience and a newer oral agent whose long-term performance profile is still being characterized.

In this Special Report segment, Bruce Strober, MD, PhD, Clinical Professor of Dermatology at Yale University School of Medicine, contextualizes these comparative data within the broader framework of how clinicians should weigh efficacy differences against route-of-administration preferences and long-term durability when making individual prescribing decisions. He emphasizes that the goal of comparative effectiveness data is not to produce a single rank-ordered list of agents but to equip clinicians with a principled basis for matching the right therapy to the right patient — and that matching requires accounting for what is known and what remains unknown about each option's long-term performance. For patients who prioritize maximum skin clearance and value the extensive safety and durability record of an established biologic, the data support risankizumab as a well-characterized, high-performing choice. For patients who prioritize oral administration and for whom the efficacy ceiling of an oral agent is clinically acceptable, icotrakinra represents a genuine advance. The decision between them is not a question of one therapy being categorically superior but of which profile best aligns with an individual patient's disease characteristics, preferences, and tolerance for uncertainty about long-term outcomes.